Skip to main content

Company ESG Risk Ratings

Zhejiang Huahai Pharmaceutical Co., Ltd.

Industry Group: Pharmaceuticals

Country/Region: China

Identifier: SHG:600521

Full time employees: 8,221

ESG Risk Rating

Comprehensive
39.9
High Risk
0-10
10-20
20-30
30-40
40+

Ranking

Industry Group (1st = lowest risk)

Pharmaceuticals 816 out of 851


Universe

Global Universe 13906 out of 15104


Last Full Update: Oct 11, 2023
Last Update: May 23, 2024

What are the ESG Risk Ratings?

Compare Zhejiang Huahai Pharmaceutical Co., Ltd. with other industry peers.

Industry Comparison

Company ESG Risk Rating Industry Rank
Jiangsu Nhwa Pharmaceutical Co., Ltd.
29.4
 
 
 
 
 
Medium
417 out of 851
Laurus Labs Ltd.
33.7
 
 
 
 
 
High
606 out of 851
CymaBay Therapeutics, Inc.
36.9
 
 
 
 
 
High
741 out of 851
China National Medicines Co., Ltd.
39.1
 
 
 
 
 
High
802 out of 851
Zhejiang Huahai Pharmaceutical Co., Ltd.
39.9
 
 
 
 
 
High
816 out of 851

For corporate professionals interested in direct competitor insights

Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.

Our Approach to Calculating ESG Risk

The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.

Zhejiang Huahai Pharmaceutical Co., Ltd.'s Exposure is Medium

Low
Medium
High

Management

Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.

Zhejiang Huahai Pharmaceutical Co., Ltd.'s Management of ESG Material Risk is Weak

Weak
Average
Strong

How do the ESG Risk Ratings work?

Top Material ESG Issues for Zhejiang Huahai Pharmaceutical Co., Ltd.

Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.

blurred material ESG issues

What are Material ESG Issues?

Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.

Controversy Rating

Highest Controversy level that has impacted Zhejiang Huahai Pharmaceutical Co., Ltd.'s ESG Risk Rating in the last three years

Highest Controversy Level

blurred controversy level

Contributing Events

blurred controversy events

Highest Controversy Events Locations

world map blurred
Get in Touch Contact us to learn more about our Controversies Research Report

Learn how the ESG Risk Ratings are used by our clients

Corporates

Leverage Sustainalytics' ESG Risk Ratings to understand and promote your corporate ESG performance with internal and external stakeholders.

Banks and Lenders

Banks and lenders can use our ESG Risk Ratings and data as a part of a broader analysis of their clients as well as for innovative product solutions such as sustainability linked loans.

Investors

The ESG Risk Ratings can help investors to identify, understand and manage ESG risks at the security and portfolio level with the aim of improving the long-term performance of their equity and fixed income securities.